case_images: PMC11705363_01
case_images: Clinical presentation of the patient with severe atopic dermatitis and CTLA-4 immunodeficiency prior to initiation of dupilumab (scores BSA 30%, IGA 4, EASI 32.4, and DLQI 25; a-d). The patient provided informed consent for the publication of these anonymized images and reports.
case_images: 10.1177_2050313X241311042-fig1.jpg
case_images: PMC11705363_01_10.1177_2050313X241311042-fig1.jpg
case_images: fig1-2050313X241311042
case_images: The patient's clinical evaluation included a body surface area (BSA) involvement of 30%, an investigator global assessment (IGA) score of 4, an Eczema Area and Severity Index (EASI) score of 32.4, and a Dermatology Life Quality Index (DLQI) score of 25 (Figure 1 ).
case_images: Clinical presentation of the patient with severe atopic dermatitis and CTLA-4 immunodeficiency 6 months after initiation of Dupilumab (scores BSA 6%, EASI 5.4 and DLQI 9). (a, b) Mild patchy eczema on forearms. (c, d) Improved eczema on hands with persistent eroded lichenified papules dorsal hands.
case_images: 10.1177_2050313X241311042-fig2.jpg
case_images: PMC11705363_01_10.1177_2050313X241311042-fig2.jpg
case_images: fig2-2050313X241311042
case_images: In August 2023, the patient started Dupilumab, and within 6 months, his eczema severity scores improved dramatically with a sixfold reduction in the EASI (5.4), fivefold reduction in BSA (6%), and almost a threefold decrease in the DLQI (Figure 2).